Parnell Pharmaceuticals Holdings Ltd
PARN
PARN was delisted on the 30th of December, 2016.
16 hedge funds and large institutions have $6.17M invested in Parnell Pharmaceuticals Holdings Ltd in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 15 → 16 (+1)
47% less capital invested
Capital invested by funds: $11.5M → $6.17M (-$5.37M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$41.3K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$33.9K |
| 3 |
AP
Atwood & Palmer
Kansas City,
Missouri
|
+$19K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$137K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$119K |
| 3 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$71.2K |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
-$50.5K |
| 5 |
Goldman Sachs
New York
|
-$49.6K |
PARN Hedge Fund Activity: Q1 2016 in Review
16 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Parnell Pharmaceuticals Holdings Ltd (PARN) for Q1 2016, worth a combined $6.17M — down 47% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PARN positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock Advisors, adding an estimated $41.3K. The largest seller was Endurant Capital Management, cutting an estimated $137K.
- 16 institutional investors held Parnell Pharmaceuticals Holdings Ltd (PARN) as of Q1 2016, up from 15 in Q4 2015.
- Funds reported $6.17M of Parnell Pharmaceuticals Holdings Ltd stock for Q1 2016, down 47% quarter-over-quarter.
- 3 funds opened new Parnell Pharmaceuticals Holdings Ltd positions in Q1 2016 and 2 closed out, a net change of +1 holder.
- The largest Parnell Pharmaceuticals Holdings Ltd buyer in Q1 2016 was BlackRock Advisors, an estimated $41.3K added.
- The largest Parnell Pharmaceuticals Holdings Ltd seller in Q1 2016 was Endurant Capital Management, an estimated $137K sold.
Based on aggregated 13F filings for Q1 2016.